Tenaya Therapeutics Announces Board and Executive Changes
Ticker: TNYA · Form: 8-K · Filed: Jul 25, 2024
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Tenaya Therapeutics is shuffling its board and exec pay structure as of July 19, 2024.
AI Summary
Tenaya Therapeutics, Inc. announced on July 19, 2024, changes related to its board of directors and executive compensation. Specifically, the company reported the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, potentially impacting investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of corporate governance and executive compensation changes, with no immediate financial implications disclosed.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Registrant
- July 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- South San Francisco, CA (location) — Principal executive offices
FAQ
What specific roles did the departing directors or officers hold?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify their individual roles or names.
Who are the newly elected directors?
The filing states that directors were elected but does not provide their names or any biographical information.
What are the details of the compensatory arrangements for certain officers?
The filing mentions adjustments to 'Compensatory Arrangements of Certain Officers' but does not disclose the specific terms or amounts of these arrangements.
What is the reason for the departure of the directors or officers?
The filing does not provide any specific reasons for the departure of directors or officers.
When did these changes become effective?
The date of the earliest event reported is July 19, 2024, indicating these changes were effective on or around this date.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-07-25 16:02:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TNYA The Nasdaq
Filing Documents
- d868248d8k.htm (8-K) — 22KB
- 0001193125-24-184817.txt ( ) — 145KB
- tnya-20240719.xsd (EX-101.SCH) — 3KB
- tnya-20240719_lab.xml (EX-101.LAB) — 18KB
- tnya-20240719_pre.xml (EX-101.PRE) — 11KB
- d868248d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENAYA THERAPEUTICS, INC. By: /s/ Jennifer Drimmer Rokovich Jennifer Drimmer Rokovich General Counsel and Secretary Date: July 25, 2024